<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The gene defect responsible for the <z:hpo ids='HP_0001417'>X-linked</z:hpo> <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> (XLP) is associated with an impaired control of Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The gene has been recently identified and the encoded protein (designated SH2D1A, DSHP or SAP) was characterized </plain></SENT>
<SENT sid="2" pm="."><plain>It is a 128 amino acid (aa) protein, containing a single Src homology 2 (SH2) domain </plain></SENT>
<SENT sid="3" pm="."><plain>It interacts with signaling lymphocytic activation molecule (SLAM) expressed on the surface of activated T and B cells </plain></SENT>
<SENT sid="4" pm="."><plain>We show that activated T, but not activated B, cells express the SH2D1A protein </plain></SENT>
<SENT sid="5" pm="."><plain>NK cells express the protein as well </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> lines originating from B, T or NK cells exhibited similar SH2D1A protein expression as the corresponding <z:mpath ids='MPATH_458'>normal</z:mpath> cells, with some notable exceptions </plain></SENT>
<SENT sid="7" pm="."><plain>EBV-carrying, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> phenotype representative (type I), but not EBV-carrying lymphoblastoid cell line (LCL)-like (type III) or EBV-negative Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) lines expressed SH2D1A </plain></SENT>
<SENT sid="8" pm="."><plain>The phenotypic switch from type I to type III in the EBV-carrying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> line Mutu was associated with a down-regulation of SH2D1A and up-regulation of SLAM </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast to <z:mpath ids='MPATH_458'>normal</z:mpath> ex vivo and long-term activated NK cells, 2 of 3 NK <z:hpo ids='HP_0001909'>leukemia</z:hpo> lines expressed SLAM </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 3 lines expressed SH2D1A, like their <z:mpath ids='MPATH_458'>normal</z:mpath> counterparts </plain></SENT>
</text></document>